Has the time come for a systematic top-down approach in Crohn's disease?
- PMID: 38604192
- DOI: 10.1016/S2468-1253(24)00073-6
Has the time come for a systematic top-down approach in Crohn's disease?
Conflict of interest statement
MF has received consulting or lecture fees from AbbVie, Amgen, Arena, Biogen, Celltrion, CTMA, Galapagos, Janssen, MSD, Pfizer, Takeda, Tillotts, MSD, Gilead, Fresenius, Celgene, Sandoz, and Ferring. AB has received consulting fees from AbbVie, Amgen, Arena, Biogen, Celltrion, CTMA, Fresenius-Kabi, Galapagos, Janssen, MSD, Nexbiome, Pfizer, Roche, Takeda, and Tillott; lecture fees from AbbVie, Amgen, Biogen, Fresenius-Kabi, Galapagos, Janssen, Mayoli-Spindler, MSD, Norgine, Pfizer, Roche, Takeda, Tillotts, and Vifor Pharma; and research grants from AbbVie, Celltrion, Janssen, Lilly, Pfizer, and Takeda.
Comment on
-
A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn's disease (PROFILE): a multicentre, open-label randomised controlled trial.Lancet Gastroenterol Hepatol. 2024 May;9(5):415-427. doi: 10.1016/S2468-1253(24)00034-7. Epub 2024 Feb 22. Lancet Gastroenterol Hepatol. 2024. PMID: 38402895 Free PMC article. Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical